MXPA06014768A - Analogos de epitopes. - Google Patents

Analogos de epitopes.

Info

Publication number
MXPA06014768A
MXPA06014768A MXPA06014768A MXPA06014768A MXPA06014768A MX PA06014768 A MXPA06014768 A MX PA06014768A MX PA06014768 A MXPA06014768 A MX PA06014768A MX PA06014768 A MXPA06014768 A MX PA06014768A MX PA06014768 A MXPA06014768 A MX PA06014768A
Authority
MX
Mexico
Prior art keywords
analogs
residues
mhc
epitope analogs
norvaline
Prior art date
Application number
MXPA06014768A
Other languages
English (en)
Spanish (es)
Inventor
David C Diamond
Liping Liu
Adrian Bot
Zhidong Xie
Original Assignee
Mannkind Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mannkind Corp filed Critical Mannkind Corp
Publication of MXPA06014768A publication Critical patent/MXPA06014768A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MXPA06014768A 2004-06-17 2005-06-17 Analogos de epitopes. MXPA06014768A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58100104P 2004-06-17 2004-06-17
US58096204P 2004-06-17 2004-06-17
PCT/US2005/021609 WO2006009920A2 (en) 2004-06-17 2005-06-17 Epitope analogs

Publications (1)

Publication Number Publication Date
MXPA06014768A true MXPA06014768A (es) 2007-06-22

Family

ID=35198081

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA06014768A MXPA06014768A (es) 2004-06-17 2005-06-17 Analogos de epitopes.

Country Status (10)

Country Link
US (5) US8354380B2 (https=)
EP (2) EP1765858B1 (https=)
JP (2) JP5166025B2 (https=)
KR (2) KR20070056042A (https=)
AU (1) AU2005265182B2 (https=)
CA (1) CA2571168A1 (https=)
IL (2) IL180101A (https=)
MX (1) MXPA06014768A (https=)
SG (1) SG153827A1 (https=)
WO (1) WO2006009920A2 (https=)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6977074B2 (en) * 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
US7178491B2 (en) * 2003-06-05 2007-02-20 Caterpillar Inc Control system and method for engine valve actuator
US20060159689A1 (en) * 2004-06-17 2006-07-20 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
US20060008468A1 (en) * 2004-06-17 2006-01-12 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
CA2571168A1 (en) * 2004-06-17 2006-01-26 Mannkind Corporation Mhc i-binding ssx-241-49 variants
US20050287068A1 (en) * 2004-06-17 2005-12-29 Bot Adrian I Efficacy of active immunotherapy by integrating diagnostic with therapeutic methods
PL1833506T3 (pl) * 2004-12-29 2016-01-29 Mannkind Corp Zastosowanie kompozycji zawierających różne antygeny związane z nowotworem jako szczepionek przeciwnowotworowych
EP1838338A2 (en) * 2004-12-29 2007-10-03 Mannkind Corporation Methods to trigger, maintain and manipulate immune responses by targeted administration of biological response modifiers into lymphoid organs
CA2592972A1 (en) * 2004-12-29 2006-07-06 Mannkind Corporation Methods to bypass cd+4 cells in the induction of an immune response
JP2008526763A (ja) * 2004-12-29 2008-07-24 マンカインド コーポレイション 予防又は治療目的のｍｈｃクラスｉ拘束性エピトープに対する免疫応答の誘導、増強及び保持方法
SG162817A1 (en) 2005-06-17 2010-07-29 Mannkind Corp Methods and compositions.to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma
NZ564359A (en) * 2005-06-17 2011-09-30 Mannkind Corp Analogs of pepetides corresponding to class I MHC-restricted T cell epitopes
AU2006259221B8 (en) 2005-06-17 2013-02-07 Mannkind Corporation Multivalent entrain-and-amplify immunotherapeutics for carcinoma
US20070192033A1 (en) * 2006-02-16 2007-08-16 Microsoft Corporation Molecular interaction predictors
US8706421B2 (en) * 2006-02-16 2014-04-22 Microsoft Corporation Shift-invariant predictions
US8396671B2 (en) * 2006-02-16 2013-03-12 Microsoft Corporation Cluster modeling, and learning cluster specific parameters of an adaptive double threading model
CN1850855B (zh) * 2006-05-26 2012-08-29 厦门大学 用于免疫或制备单克隆抗体的方法和组合物
JP2009544610A (ja) * 2006-07-14 2009-12-17 マンカインド コーポレイション 予防又は治療目的のためにｍｈｃクラスｉ拘束エピトープに対する免疫応答を引き出し、増強し、保持する方法
ES2709176T3 (es) 2006-08-11 2019-04-15 Life Sciences Res Partners Vzw Péptidos inmunogénicos y su uso en trastornos inmunitarios
US8121797B2 (en) * 2007-01-12 2012-02-21 Microsoft Corporation T-cell epitope prediction
CN103736086A (zh) * 2007-02-15 2014-04-23 曼康公司 用于增强t细胞应答的方法
CN101687022B (zh) 2007-03-26 2016-09-07 莱顿大学医学中心附属莱顿教学医院 Prame衍生的肽以及包括该肽的免疫原组合物
WO2008148068A1 (en) * 2007-05-23 2008-12-04 Mannkind Corporation Multicistronic vectors and methods for their design
EP2626081B1 (en) 2008-02-14 2017-03-22 Life Sciences Research Partners VZW Immunogenic control of tumours and tumour cells
AU2010310468A1 (en) * 2009-10-23 2012-05-24 Mannkind Corporation Cancer immunotherapy and method of treatment
CN102869682B (zh) 2009-11-18 2016-10-19 曼康公司 单克隆抗体及其诊断用途
CN105601727B (zh) * 2010-03-11 2020-01-10 肿瘤疗法科学股份有限公司 Hjurp肽及包含它们的疫苗
US9109007B2 (en) 2010-08-18 2015-08-18 Purdue Pharma L.P. MHC-I restricted epitopes containing non-natural amino acid residues
CN103124740B (zh) 2010-09-21 2015-09-02 美国卫生和人力服务部 抗-ssx-2t细胞受体和相关材料及使用方法
DE11787873T1 (de) 2010-11-25 2013-12-12 Imnate Sarl Immugene Peptide zur Verwendung bei der Vorbeugung und/oder Behandlung von Infektionskrankheiten, Autoimmunerkrankungen, Immunreaktionen auf Allofaktoren, allergischen Erkrankungen, Tumoren, Transplantatabstossungen und Immunreaktionen auf virale Vektoren
WO2012076059A1 (en) * 2010-12-09 2012-06-14 Stichting Het Nederlands Kanker Instituut Immune restricted peptides with increased efficacy
WO2012088414A1 (en) 2010-12-23 2012-06-28 Ludwig Institute For Cancer Research Ltd. Liposomal formulation of nonglycosidic ceramides and uses thereof
GB201201511D0 (en) 2012-01-30 2012-03-14 Univ Leuven Kath Modified epitopes for boosting CD4+ T-cell responses
GB201309469D0 (en) 2013-05-28 2013-07-10 Imcyse Sa Detection of CD4+ T lymphocytes
US9228207B2 (en) 2013-09-06 2016-01-05 President And Fellows Of Harvard College Switchable gRNAs comprising aptamers
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
US10077453B2 (en) 2014-07-30 2018-09-18 President And Fellows Of Harvard College CAS9 proteins including ligand-dependent inteins
GB201418433D0 (en) 2014-10-17 2014-12-03 Imcyse Sa Novel immunogenic peptides
US10729791B2 (en) 2015-05-18 2020-08-04 Imcyse Sa Animal models for evaluating pharmaceutical compounds
IL310721B2 (en) 2015-10-23 2025-11-01 Harvard College Nucleobase editors and uses thereof
US12390514B2 (en) 2017-03-09 2025-08-19 President And Fellows Of Harvard College Cancer vaccine
EP3592853A1 (en) 2017-03-09 2020-01-15 President and Fellows of Harvard College Suppression of pain by gene editing
US11542496B2 (en) 2017-03-10 2023-01-03 President And Fellows Of Harvard College Cytosine to guanine base editor
CN111801345A (zh) 2017-07-28 2020-10-20 哈佛大学的校长及成员们 使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物
US12406749B2 (en) 2017-12-15 2025-09-02 The Broad Institute, Inc. Systems and methods for predicting repair outcomes in genetic engineering
US12522807B2 (en) 2018-07-09 2026-01-13 The Broad Institute, Inc. RNA programmable epigenetic RNA modifiers and uses thereof
WO2020051566A1 (en) * 2018-09-07 2020-03-12 Immunotope, Inc. Vaccines with enhanced immune response and methods for their preparation
WO2020092453A1 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Nucleobase editors comprising geocas9 and uses thereof
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
WO2020191233A1 (en) 2019-03-19 2020-09-24 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
US12473543B2 (en) 2019-04-17 2025-11-18 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
AU2023241306B2 (en) * 2022-10-05 2024-10-03 Tscan Therapeutics, Inc. Prame immunogenic peptides, binding proteins recognizing prame immunogenic peptides, and uses thereof

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5241047A (en) * 1988-12-08 1993-08-31 Biochem Pharma Inc. Synthetic peptides and mixtures thereof for detecting HIV antibodies
US6417165B1 (en) * 1988-03-27 2002-07-09 Ludwig Institute For Cancer Research NY-ESO-1-peptide derivatives, and uses thereof
US5804381A (en) * 1996-10-03 1998-09-08 Cornell Research Foundation Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof
DE4128684A1 (de) * 1991-08-29 1993-03-04 Behringwerke Ag Hcmv-spezifische peptide, mittel dazu und ihre verwendung
US5662907A (en) * 1992-08-07 1997-09-02 Cytel Corporation Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes
DE69334071T2 (de) * 1992-11-05 2007-10-25 Sloan-Kettering Institute For Cancer Research Prostata-spezifisches membranantigen
US5747271A (en) 1992-12-22 1998-05-05 Ludwig Institute For Cancer Research Method for identifying individuals suffering from a cellular abnormality some of whose abnormal cells present complexes of HLA-A2/tyrosinase derived peptides, and methods for treating said individuals
US5620886A (en) * 1993-03-18 1997-04-15 Ludwig Institute For Cancer Research Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
US5935818A (en) * 1995-02-24 1999-08-10 Sloan-Kettering Institute For Cancer Research Isolated nucleic acid molecule encoding alternatively spliced prostate-specific membrane antigen and uses thereof
US5874560A (en) * 1994-04-22 1999-02-23 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods
US5830753A (en) 1994-09-30 1998-11-03 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor dage and uses thereof.
US6025191A (en) * 1995-06-07 2000-02-15 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which encode a melanoma specific antigen and uses thereof
US5821122A (en) * 1995-06-07 1998-10-13 Inserm (Institute Nat'l De La Sante Et De La Recherche . .) Isolated nucleic acid molecules, peptides which form complexes with MHC molecule HLA-A2 and uses thereof
US6548064B1 (en) * 1997-05-05 2003-04-15 Ludwig Institute For Cancer Research Isolated peptides consisting of amino acid sequences found in SSX or NY-ESO-1 molecules, which bind to HLA molecules
US6025470A (en) 1997-06-23 2000-02-15 Ludwig Institute For Cancer Research Isolated nona- and decapeptides which bind to HLA molecules, and the use thereof
ES2265165T3 (es) 1997-07-10 2007-02-01 Mannkind Corporation Dispositivo para inducir una respuesta ltc.
US6994851B1 (en) * 1997-07-10 2006-02-07 Mannkind Corporation Method of inducing a CTL response
US6977074B2 (en) * 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
US6576755B1 (en) * 1997-09-10 2003-06-10 Zymogenetics, Inc. Beta-defensins
US6709844B1 (en) 2000-11-16 2004-03-23 Mannkind Corporation Avoidance of undesirable replication intermediates in plasmid propagation
US20030138808A1 (en) 1998-02-19 2003-07-24 Simard John J.L. Expression vectors encoding epitopes of target-associated antigens
US20020072493A1 (en) * 1998-05-19 2002-06-13 Yeda Research And Development Co. Ltd. Activated T cells, nervous system-specific antigens and their uses
US6777388B1 (en) * 1998-08-21 2004-08-17 Clf Medical Technology Acceleration Program, Inc. Leptin-related peptides
GB9818938D0 (en) * 1998-08-28 1998-10-21 Alpharma As Bioactive peptides
JP4699612B2 (ja) * 1999-02-05 2011-06-15 ザ ユニバーシティ オブ メルボーン Ｔヘルパー細胞エピトープ
US7157091B1 (en) * 1999-06-18 2007-01-02 Ludwig Institute For Cancer Research MAGE-A1 peptides presented by HLA class II molecules
AU781044B2 (en) * 1999-11-05 2005-05-05 Axonyx, Inc. Peptide analogs and mimetics suitable for in vivo use in the treatment of diseases associated with abnormal protein folding into amyloid, amyloid-like deposits or beta-sheet rich pathological precursor thereof
US6605711B1 (en) * 1999-11-15 2003-08-12 Ludwig Institute For Cancer Research NY-ESO-1 peptide derivatives, and uses thereof
JP4615805B2 (ja) * 1999-11-15 2011-01-19 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ Ｎｙ−ｅｓｏ−１ペプチド誘導体およびその使用
EP1230268B1 (en) * 1999-11-18 2009-10-14 Pharmexa Inc. Heteroclitic analogs of class i epitopes
EP1118860A1 (en) * 2000-01-21 2001-07-25 Rijksuniversiteit te Leiden Methods for selecting and producing T cell peptide epitopes and vaccines incorporating said selected epitopes
CA2400215A1 (en) 2000-02-23 2001-08-30 Epimmune Inc. Hla binding peptides and their uses
EP1272509A2 (en) * 2000-04-05 2003-01-08 V.I. Technologies, Inc. Prion-binding peptidic ligands and methods of using same
US6861234B1 (en) * 2000-04-28 2005-03-01 Mannkind Corporation Method of epitope discovery
US20030215425A1 (en) * 2001-12-07 2003-11-20 Simard John J. L. Epitope synchronization in antigen presenting cells
US7252824B2 (en) 2001-03-07 2007-08-07 Mannkind Corporation Anti-neovasculature preparations for cancer
WO2003008537A2 (en) * 2001-04-06 2003-01-30 Mannkind Corporation Epitope sequences
US20030148973A1 (en) * 2001-05-23 2003-08-07 Peter Emtage MAGE-A1 peptides for treating or preventing cancer
US20030017134A1 (en) * 2001-06-19 2003-01-23 Technion Research And Development Foundation Ltd. Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer
CN101024842A (zh) * 2001-11-07 2007-08-29 曼康公司 编码靶相关抗原表位的表达载体及其设计方法
US20060128607A1 (en) * 2002-01-29 2006-06-15 Anja-Katrin Bosserhoff Method for inhibiting "melanoma inhibitory activity" mia
US6992176B2 (en) * 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
US8802618B2 (en) 2002-03-08 2014-08-12 Board Of Regents, The University Of Texas System Controlled modulation of amino acid side chain length of peptide antigens
AU2003274463B2 (en) * 2002-06-10 2009-10-29 University Of Rochester Gene differentially expressed in breast and bladder cancer and encoded polypeptides
US20070105779A1 (en) * 2002-07-31 2007-05-10 Danila Valmori Isolated, ssx-2 and ssx-2 related peptides useful as hla binders and ctl epitopes, and uses thereof
EP2181595A1 (en) * 2002-08-16 2010-05-05 Yeda Research And Development Company Ltd. Tumor associated antigen, peptides thereof, and use of same as anti-tumor vaccines
AU2003270311A1 (en) 2002-09-06 2004-03-29 Mannkind Corporation Epitope sequences
CA2499123A1 (en) * 2002-09-17 2004-04-15 Antigen Express, Inc. Ii-key/antigenic epitope hybrid peptide vaccines
AU2004249254B2 (en) 2003-06-17 2010-07-08 Mannkind Corporation Combinations of tumor-associated antigens for the treatment of various types of cancers
DK1635863T3 (da) * 2003-06-17 2010-11-22 Mannkind Corp Sammensætninger til udløsning, forbedring og opretholdelse af immunresponser mod MHC-klasse-i-begrænsede epitoper til profylaktiske eller terapeutiske formål
US20050287068A1 (en) * 2004-06-17 2005-12-29 Bot Adrian I Efficacy of active immunotherapy by integrating diagnostic with therapeutic methods
CA2571168A1 (en) 2004-06-17 2006-01-26 Mannkind Corporation Mhc i-binding ssx-241-49 variants
US20060159689A1 (en) * 2004-06-17 2006-07-20 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
US20060008468A1 (en) * 2004-06-17 2006-01-12 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
EP1838338A2 (en) * 2004-12-29 2007-10-03 Mannkind Corporation Methods to trigger, maintain and manipulate immune responses by targeted administration of biological response modifiers into lymphoid organs
PL1833506T3 (pl) * 2004-12-29 2016-01-29 Mannkind Corp Zastosowanie kompozycji zawierających różne antygeny związane z nowotworem jako szczepionek przeciwnowotworowych
JP2008526763A (ja) * 2004-12-29 2008-07-24 マンカインド コーポレイション 予防又は治療目的のｍｈｃクラスｉ拘束性エピトープに対する免疫応答の誘導、増強及び保持方法
US9469902B2 (en) 2014-02-18 2016-10-18 Lam Research Corporation Electroless deposition of continuous platinum layer
EP3636238B1 (en) 2018-10-12 2021-04-28 Liko Research & Development AB Gates with transition ramps for overhead lifting rails

Also Published As

Publication number Publication date
IL209859A0 (en) 2011-02-28
KR20070056042A (ko) 2007-05-31
US20110301327A1 (en) 2011-12-08
US20060063913A1 (en) 2006-03-23
EP2332971B1 (en) 2016-02-17
EP1765858B1 (en) 2012-11-21
EP2332971A1 (en) 2011-06-15
JP2008283979A (ja) 2008-11-27
CA2571168A1 (en) 2006-01-26
US8202841B2 (en) 2012-06-19
SG153827A1 (en) 2009-07-29
KR20100092031A (ko) 2010-08-19
JP5166025B2 (ja) 2013-03-21
US20060094661A1 (en) 2006-05-04
US8354380B2 (en) 2013-01-15
IL180101A0 (en) 2007-05-15
EP1765858A2 (en) 2007-03-28
IL180101A (en) 2014-02-27
JP2008510453A (ja) 2008-04-10
US20060057673A1 (en) 2006-03-16
US20130195901A1 (en) 2013-08-01
WO2006009920A2 (en) 2006-01-26
AU2005265182B2 (en) 2012-06-21
WO2006009920A3 (en) 2006-06-15
AU2005265182A1 (en) 2006-01-26

Similar Documents

Publication Publication Date Title
SG153827A1 (en) Epitope analogs
WO2006138562A3 (en) Epitope analogues
IL267186A (en) Epitopes of regulated T cells, preparations and uses
MX338940B (es) Identificacion de epitopos ige novedosos.
AR117007A2 (es) Región constante de anticuerpo mutante
NZ593833A (en) Extended recombinant polypeptides and compositions comprising same
PH12020500677A1 (en) Neoantigens and uses thereof
MX382293B (es) Predicción de inmunogenicidad en epítopos de células t.
IL190705A0 (en) A method for the production of a permanent human cell line
EA201101660A8 (ru) Бифункциональные полипептиды
MX2009012420A (es) Reovirus mutantes y metodos para elaboracion y uso.
PE20121564A1 (es) Polipeptidos anti-tnfr1 estables, dominios variables de anticuerpos y antagonistas
WO2007089038A8 (ja) 新規ホスホリパーゼｄ
BR0313135A (pt) Epìtopos de células t em eritropoietina
WO2007055823A3 (en) Gpcr expressing cell lines and antibodies
NZ591133A (en) Novel melanoma antigen peptide and uses thereof
BRPI0508916A (pt) polipeptìdeos hìbridos imunogênicos antiobesidade e composição de vacina antiobesidade compreendendo-os
UA100692C2 (ru) Днк-плазмиды, имеющие повышенную экспрессию и стабильность
WO2024123975A3 (en) A t cell receptor recognizing an unmutated foxm1 epitope presented on hla-a*02:01
LT2005043A (en) Process for preparing monoclonal antibodies; hybridoma cell lines generated by this process and recombinant chimeric virus-like particles with inserted foreign protein fragments as immunogenes to generate hybridomas by this process
MX2013007007A (es) Vacunas a base de peptidos de la proteina c5a de complemento.
PE20190967A1 (es) Aislados modificados de streptomyces fungicidicus y su uso
EP1885867A4 (en) NEW PROCEDURES
MX2024000941A (es) Péptidos y receptores manipulados de linfocitos t dirigidos a antígenos fanci, rad51 y pbk y métodos de uso.
DE602005025989D1 (de) Von 2',3'-didesoxynucleosiden und 2',3'-didehydro-2',3'-didesoxynucleosiden

Legal Events

Date Code Title Description
FG Grant or registration